MAPS is delighted to report an important milestone towards a randomized clinical trial at the Veterans Affairs (VA) Administration, where so many of our nation’s veterans are treated for PTSD. The U.S. Food and Drug Administration (FDA) has recently agreed to the first protocol submitted by MAPS in partnership with esteemed PTSD researcher Rachel Yehuda, Ph.D., through the VA’s investigator-initiated research program. She and her team plan to conduct this trial at the VA pending institutional and regulatory approvals.
